In This Section

Program: Thursday, February 19

Wednesday, Feb. 18 Friday, Feb 20 Saturday, Feb. 21

THURSDAY, FEBRUARY 19

* – Short talk selected from proffered abstracts

Thursday, February 19

Breakfast

7-8:30 a.m. | Diamond Ballroom 1-3

Keynote Session 2

8:30-9:15 a.m. | Diamond Ballroom 5-10

  • 8:30 a.m. | Introduction of Keynote Speaker
    Nina Bhardwaj
  • 8:35 a.m. | Keynote
    Rafi Ahmed, Emory University, Atlanta, Georgia

Break

9:15-9:30 a.m. | Diamond Ballroom Foyer

Major Symposia 1-2

9:30-11 a.m.

Major Symposium 1: Cellular Therapies for Solid Cancers

Diamond Ballroom 5-10

Session Chair: Christian S. Hinrichs, Rutgers Cancer Institute of New Jersey, Piscataway, New Jersey

  • 9:35 a.m. | Christian S. Hinrichs
  • 9:55 a.m. | Programming CAR-T cells with drug-regulated cytokine signals and multi-gene cargo delivery
    Louai Labanieh, Icahn School of Medicine at Mount Sinai, New York, New York
  • 10:15 a.m. | A versatile microRNA-based platform for activation-dependent regulation of armored CAR T cell payloads*
    Nina Barceló-Genestar, IDIBAPS, Barcelona, Spain
  • 10:25 a.m. | IL-12 armored anti-macrophage CAR T cells reset and reprogram the tumor microenvironment to control metastatic ovarian and lung tumor growth*
    Jaime Mateus-tique, Icahn School of Medicine, New York, New York
  • 10:35 a.m. | Discussion / Q&A

Major Symposium 2: Immune Suppressive Myeloid Cells

Diamond Ballroom 4

Session Chair: Renato Ostuni, IRCCS Ospedale San Raffaele, Milan, Italy

  • 9:35 a.m. | Spatial and molecular control of tumor immune microenvironment
    Renato Ostuni
  • 9:55 a.m. | STING-mediated myeloid reprogramming drives immunotherapy response in DNA repair mutant tumors*
    Robert M. Samstein, Icahn School of Medicine at Mount Sinai, New York, New York
  • 10:05 a.m. | Epithelial alarmins coordinate type 2 immunity in colorectal cancer*
    Thornton Thompson, University of Washington, Seattle, Washington
  • 10:15 a.m. | Discussion / Q&A

Break

11-11:15 a.m. | Diamond Ballroom Foyer

Spotlight on Proffered Papers Session 2

11:15 a.m.-12 p.m. | Diamond Ballroom 5-10

Session Chair: Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, New York

  • 11:19 a.m. | Peripheral immune dynamics and biomarkers of clinical response in patients with castration-resistant prostate cancer treated with combination immunotherapy*
    Nicole J. Toney, National Cancer Institute, Bethesda, Maryland
  • 11:26 a.m. | Impact of polyethylene glycol bowel preparation on the gut microbiome composition and response to immune checkpoint inhibition*
    Yongjia Hu, Research Center of the Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal, Quebec, Canada
  • 11:33 a.m. | Spatial multi-omics identifies a tumor microenvironment signature predictive of immunotherapy response in mucosal melanomas*
    Suhendan Ekmekcioglu, Cleveland Clinic, Cleveland, Ohio
  • 11:40 a.m. | Insights into immunotherapy response, irAEs, and pre-treatment conditions impacting patient outcomes from the largest plasma proteomics study of patients receiving immune checkpoint inhibitor therapy*
    Jerid Robinson, Nomic Bio, Montreal, Quebec, Canada

Poster Session B / Exhibit Show / Lunch

12:15-3:15 p.m. | Platinum Ballroom

Major Symposia 3-4

3:15-4:15 p.m.

Major Symposium 3: Regulation of Immune Response to Cancer

Diamond Ballroom 5-10

Session Chair: Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 3:20 p.m. | From the clinic to the lab: Investigating mechanisms of response and resistance to immune checkpoint therapy
    Padmanee Sharma
  • 3:40 p.m. | The T cell ‘exhaustion’ transcriptional program downstream of NFAT
    Patrick Hogan, La Jolla Institute for Immunology, La Jolla, California
  • 4 p.m. | Discussion / Q&A

Major Symposium 4: NK Cells in IO

Diamond Ballroom 4

Session Chair: Katayoun Rezvani, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 3:20 p.m. | Optimizing NK cell engineering for therapeutic efficacy
    Katayoun Rezvani
  • 3:40 p.m. | Reprogramming NK cells to overcome tumor immunosuppression
    Rizwan Romee, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 4 p.m. | Discussion / Q&A

Break

4:15-4:25 p.m. | Diamond Ballroom Foyer

Spotlight on Proffered papers session 3

4:25-5 p.m. | Diamond Ballroom 5-10

Session Chair: Caius Radu, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California

  • 4:30 p.m. | Regulation of CTLA-4 and PD-1 blockade immunotherapy by distinct subpopulations of CD4 and CD8 tumor-resident memory T cells*
    Fathia Mami-Chouaib, INSERM-UMR1186 Gustave Roussy, Villejuif, France
  • 4:37 p.m. | Genomic and spatial immune biomarkers predictive of chemoimmunotherapy response in triple-negative breast cancer*
    Mahak Bhargava, University of Alabama, Birmingham, Alabama
  • 4:44 p.m. | Synergizing hypomethylating agents with off-the-shelf CD70-targeted CAR-engineered natural killer T cells for the treatment of acute myeloid leukemia*
    Yan-Ruide Li, University of California, Los Angeles, California
  • 4:51 p.m. | Innate lymphoid cell reprogramming reveals immunometabolic and epigenetic signatures following checkpoint blockade in head and neck squamous cell carcinoma (HNSCC)*
    Sujeetha A. Rajakumar, Johns Hopkins University School of Medicine, Baltimore, Maryland

Spotlight Sessions 1-2

5-6:15 p.m.

Spotlight Session 1: Artificial Intelligence and Design of Immune Modulators

Diamond Ballroom 5-10

Session Chair: David M. Reese, Amgen, Inc., Thousand Oaks, California

  • 5:05 p.m. | Molecular engineering in the era of artificial intelligence
    David M. Reese
  • 5:25 p.m. | When proteins become code: Generative AI for therapeutics
    Gevorg Grigoryan, Generate Biomedicines, Somerville, Massachusetts
  • 5:45 p.m. | Discussion / Q&A

Spotlight Session 2: in situ Vaccination

Diamond Ballroom 4

Session Chair: Michael J. Mitchell, University of Pennsylvania, Philadelphia, Pennsylvania

  • 5:05 p.m. | Delivery technologies for immuno-oncology
    Michael J. Mitchell
  • 5:25 p.m. | Haydn T. Kissick, Emory University, Atlanta, Georgia
  • 5:45 p.m. | Tertiary lymphoid structures generate anti-tumor immunity independently of immune responses in secondary lymphoid organs upon STING and lymphotoxin-β receptor activation*
    Yasuhiro Kikuchi, Johns Hopkins All Children’s Hospital, St. Petersburg, Florida
  • 5:55 p.m. | Discussion / Q&A

Evening off / Dinner on own

6:15 p.m.